Community/Retail

Medication nonadherence is a major cause of morbidity, especially in elderly patients.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to officials with IQVIA.

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Findings showed that LAIV was more effective in those vaccinated in both the enrollment season and the prior season than in those vaccinated only in the enrollment season.

Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.

This cannabidiol oral solution can be prescribed in the United States to treat seizures associated with Dravet or Lennox-Gastaut syndrome.

The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors.

Although HPV vaccination rates have steadily increased in recent years, more work is needed in this area to effectively reduce HPV-associated cancer, according to a new report release by the President’s Cancer Panel.

Officials with the FDA have approved Coherus BioSciences’ Udenyca™ (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

The committee jointly voted 21-2 against recommending approval, noting that the benefit-risk profile was not adequate to support approval.

This approval marks the first and only oral film approved by the FDA to treat seizures associated with Lennox-Gastaut syndrome.

Hyperkalemia increased the risk of 30-day readmissions.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

This list encompasses over 50 companies in the digital health space attempting to improve medication adherence, ranging from bioingestible sensors to smart pill bottles.

The guidelines also highlight the importance of discussions between health care providers and patients.

Florajen Probiotics announces plans to expand consumer access by increasing product availability at Walgreens and Duane Reade stores nationwide.

The test is the first of its kind to secure FDA approval.

A total of 85% of AMBER study participants (308/362) achieved virologic suppression (viral load

The recalls and returns will be managed by the respective distributors separately, according to a press release from the company.

The FDA has approved Sandoz’s biosimilar adalimumab, Hyrimoz (adalimumab-adaz) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

The expanded indication marks the first time an anti-PD-1 regimen has been approved in the first-line setting as both combination and monotherapy for squamous NSCLC, regardless of tumor PD-L1 expression status.

The CDC offers 7 tips to avoid any health scares this season.

The action, FDA officials explained in a press release, is based on new data that suggest there is no longer a reasonable certainty that there is no harm from the use of lead acetate as a color additive.

This new indication also applies to the fixed-dose combinations of canagliflozin/metformin HCl (Invokamet) tablets and canagliflozin/metformin HCl extended-release (Invokamet XR) tablets.

Avelumab, an immune checkpoint inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, significantly improved progression-free survival in untreated renal cell carcinoma.

Three hospitals made significant progress in reducing deaths associated with poor quality health care.

According to TherapeuticsMD, Bijuva is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.